Skip to content

Study · Not a test of the peptide alone · 2008

6 results

Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization.

Gao D, Zhang X, Zhang J, Cao J, Wang F

Archives of pharmacal research21 Nov 2008Cited by 17 (Europe PMC)

PMID19023544 (opens in a new tab)DOI10.1007/s12272-001-2132-z (opens in a new tab)PepBankPUB-19023544
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Activity measurement

    In an in vivo mouse experiment, the Talpha1-TP5 fusion peptide promoted macrophage phagocytosis better than Talpha1 and TP5.

    In plain wordsIn mice, a fusion of thymosin alpha1 and thymopentin boosted immune cell engulfing more than either part alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMacrophage phagocytosis
    Study

    mousen: not reported in source

    Mice
    Comparator
    Talpha1 and TP5
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    in vivo experiment it showed better activity in promoting the phagocytosis of macrophages and secretion of IL-2 than both Talpha1 and TP5.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Activity measurement

    In an in vivo mouse experiment, the Talpha1-TP5 fusion peptide promoted IL-2 secretion better than Talpha1 and TP5.

    In plain wordsIn mice, a fusion of thymosin alpha1 and thymopentin raised IL-2 release more than either part alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-2 secretion
    Study

    mousen: not reported in source

    Mice
    Comparator
    Talpha1 and TP5
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    in vivo experiment it showed better activity in promoting the phagocytosis of macrophages and secretion of IL-2 than both Talpha1 and TP5.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneEx vivo tissuePharmacokinetics

    In an in vitro plasma analysis, the Talpha1-TP5 fusion peptide had a longer half-life than TP5 and Talpha1.

    In plain wordsIn lab tests, a fusion of thymosin alpha1 and thymopentin lasted longer in plasma than thymopentin or thymosin alpha1 alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePlasma half-life of Talpha1-TP5 fusion peptide
    Study

    n: not reported in source

    Comparator
    Thymopentin (TP5) and Talpha1
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Plasma half-life
    140 min
    Talpha1-TP5 fusion peptide

    Source sentences

    Summary
    In vitro analysis showed that the plasma half-life of Talpha1-TP5 fusion peptide is 140 +/- 14 min, which is longer than that of TP5 (5.6+/-0.7 min) and Talpha1 (127+/-11 min).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04LabNot a test of Thymosin alpha-1 aloneEx vivo tissuePharmacokinetics

    In the in vitro plasma analysis, Talpha1 had a plasma half-life of 127 min.

    In plain wordsIn lab tests, thymosin alpha1 had a half-life of 127 minutes in plasma.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePlasma half-life of Talpha1
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Plasma half-life
    127 min
    Talpha1

    Source sentences

    Summary
    In vitro analysis showed that the plasma half-life of Talpha1-TP5 fusion peptide is 140 +/- 14 min, which is longer than that of TP5 (5.6+/-0.7 min) and Talpha1 (127+/-11 min).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In Kunming mouse splenocytes, the Talpha1-TP5 fusion peptide had greater activity in promoting proliferation.

    In plain wordsIn cells from mice, a fusion of thymosin alpha1 and thymopentin made immune cells multiply more.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSplenocyte proliferation
    Study

    mousen: not reported in source

    Kunming mouse splenocytes
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The in vitro activity assay presented that Talpha1-TP5 fusion peptide has greater activity in promoting proliferation of Kunming mouse splenocytes

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    Circular dichroism showed that the Talpha1-TP5 fusion peptide has mainly alpha-helix and random coil structure.

    In plain wordsIn lab tests, a fusion of thymosin alpha1 and thymopentin was mostly alpha-helix and random coil in shape.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableSecondary structure of Talpha1-TP5 fusion peptide
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The circular dichroism spectra (CD) indicated that the secondary structure of Talpha1-TP5 fusion peptide is dominated by a-helix and random coil.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.